glp-1 substance use disorder medications are getting attention for their potential in addiction care. Here's what the research is finding. #AddictionTreatment #GLP1 #EmergingResearch What 2025 Holds for GLP-1s

The LEADER trial (liraglutide), SUSTAIN-6 (semaglutide), and REWIND (dulaglutide) studies showed no significant increase in pancreatitis rates compared to placebo

A plasma eicosatrienoic acid:arachidonic acid (triene:tetraene) ratio greater than 0.2 is generally considered indicative of essential fatty acid deficiency (35, 37)

Metformin reduces liver glucose production by inhibition of fructose-1-6-bisphosphatase

Missense mutation in flavin-containing mono-oxygenase 3 gene, FMO3, underlies fish-odour syndrome

And functionally, muscle is what keeps you strong, mobile, and resilient, which matters at every age and increasingly so over time

Elevated branched-chain amino acid (BCAA) levels have been associated with insulin resistance and increased T2DM risk [350], while altered microbial carbohydrate metabolism, characterized by increased host-accessible monosaccharides in individuals with insulin resistance, may further contribute to metabolic dysfunction [351]